Patents Assigned to Beta Cat Pharmaceuticals, Inc.
  • Anthracene-9, 10-dione dioxime compound prodrugs and their uses
    Patent number: 9963475
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures; including, salts thereof that act as anti-cancer and anti-tumor agents, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: May 8, 2018
    Assignee: Beta Cat Pharmaceuticals, Inc.
    Inventors: Hariprasad Vankayalapati, Xiaohui Liu, Sunil Sharma, Srinivas Rao Kasibhatla, Seelam Venkata Reddy
  • Anthracene-9, 10-dione dioxime compound prodrugs and their uses
    Patent number: 9725473
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures; including, salts thereof that act as anti-cancer and anti-tumor agents, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 8, 2017
    Assignee: Beta Cat Pharmaceuticals, Inc.
    Inventors: Hariprasad Vankayalapati, Xiaohui Liu, Sunil Sharma, Srinivas Rao Kasibhatla, Seelam Venkata Reddy
  • Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
    Patent number: 9238030
    Abstract: Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (TBL1) activity, including myeloproliferative neoplasia, chronic myeloid leukemia, and acute myeloid leukemia.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: January 19, 2016
    Assignee: Beta Cat Pharmaceuticals, Inc.
    Inventors: Kapil N. Bhalla, Stephen Horrigan